141 related articles for article (PubMed ID: 32223918)
1. Reply to: "Switching vs. add-on strategy in PBC treatment: Lessons from UDCA and bezafibrate experience".
Harms MH; van Buuren HR; van der Meer AJ
J Hepatol; 2020 Jun; 72(6):1211-1212. PubMed ID: 32223918
[No Abstract] [Full Text] [Related]
2. Switching vs. add-on strategy in PBC treatment: Lessons from UDCA and bezafibrate experience.
Corpechot C; Rousseau A; Chazouillères O
J Hepatol; 2020 Jun; 72(6):1210-1211. PubMed ID: 32199670
[No Abstract] [Full Text] [Related]
3. Bezafibrate treatment: a new medical approach for PBC patients?
Kanda T; Yokosuka O; Imazeki F; Saisho H
J Gastroenterol; 2003; 38(6):573-8. PubMed ID: 12825134
[TBL] [Abstract][Full Text] [Related]
4. Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid.
Honda A; Ikegami T; Nakamuta M; Miyazaki T; Iwamoto J; Hirayama T; Saito Y; Takikawa H; Imawari M; Matsuzaki Y
Hepatology; 2013 May; 57(5):1931-41. PubMed ID: 22911624
[TBL] [Abstract][Full Text] [Related]
5. Bezafibrate treatment of primary biliary cirrhosis following incomplete response to ursodeoxycholic acid.
Hazzan R; Tur-Kaspa R
J Clin Gastroenterol; 2010; 44(5):371-3. PubMed ID: 19881358
[TBL] [Abstract][Full Text] [Related]
6. Additional fibrate treatment in UDCA-refractory PBC patients.
Chung SW; Lee JH; Kim MA; Leem G; Kim SW; Chang Y; Lee HY; Yoon JS; Park JY; Lee YB; Cho EJ; Yu SJ; Kim YJ; Yoon JH
Liver Int; 2019 Sep; 39(9):1776-1785. PubMed ID: 31162879
[TBL] [Abstract][Full Text] [Related]
7. Effects of Bezafibrate on Outcome and Pruritus in Primary Biliary Cholangitis With Suboptimal Ursodeoxycholic Acid Response.
Reig A; Sesé P; Parés A
Am J Gastroenterol; 2018 Jan; 113(1):49-55. PubMed ID: 29016567
[TBL] [Abstract][Full Text] [Related]
8. Fibrates as adjuvant therapy for chronic cholestatic liver disease: its time has come.
Ghonem NS; Boyer JL
Hepatology; 2013 May; 57(5):1691-3. PubMed ID: 23174993
[No Abstract] [Full Text] [Related]
9. Bezafibrate therapy in primary biliary cholangitis refractory to ursodeoxycholic acid: a longitudinal study of paired liver biopsies at 5 years of follow up.
Sorda JA; González Ballerga E; Barreyro FJ; Avagnina A; Carballo P; Paes de Lima A; Daruich J
Aliment Pharmacol Ther; 2021 Nov; 54(9):1202-1212. PubMed ID: 34587309
[TBL] [Abstract][Full Text] [Related]
10. Comment on biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis.
Walker LJ; Newton J; Jones DE; Bassendine MF
Hepatology; 2009 Jan; 49(1):337-8; author reply 338. PubMed ID: 19035342
[No Abstract] [Full Text] [Related]
11. Novel Therapies on Primary Biliary Cirrhosis.
Czul F; Levy C
Clin Liver Dis; 2016 Feb; 20(1):113-30. PubMed ID: 26593294
[TBL] [Abstract][Full Text] [Related]
12. Treatment of Primary Biliary Cholangitis: First-Line and Second-Line Therapies.
Liu CH; Bowlus CL
Clin Liver Dis; 2022 Nov; 26(4):705-726. PubMed ID: 36270725
[TBL] [Abstract][Full Text] [Related]
13. A validation study of the Ursodeoxycholic Acid Response Score in Japanese patients with primary biliary cholangitis.
Yagi M; Matsumoto K; Komori A; Abe M; Hashimoto N; Inao M; Namisaki T; Kawata K; Ninomiya M; Fujii H; Takahashi A; Kang JH; Takamura M; Arakawa M; Joshita S; Sato K; Itakura J; Nomura T; Kakisaka K; Kaneko A; Tamura Y; Miura R; Aiso M; Arizumi T; Asaoka Y; Kikuchi K; Takikawa Y; Masaki T; Umemura T; Honda A; Ohira H; Kawada N; Yoshiji H; Mochida S; Takikawa H; Tanaka A;
Liver Int; 2020 Aug; 40(8):1926-1933. PubMed ID: 32438508
[TBL] [Abstract][Full Text] [Related]
14. UDCA, PBC and biochemistry: what does normal mean?
Lindor KD
Gut; 2000 Jan; 46(1):8. PubMed ID: 10601046
[No Abstract] [Full Text] [Related]
15. [Research progress on risk factors for poor response of ursodeoxycholic acid in primary biliary cholangitis].
Yuan Z; Jia G; Han Y
Zhonghua Gan Zang Bing Za Zhi; 2019 Jan; 27(1):73-76. PubMed ID: 30685931
[TBL] [Abstract][Full Text] [Related]
16. Case of primary biliary cirrhosis-autoimmune hepatitis overlap which manifested after delivery.
Monoe K; Takahashi A; Katsushima F; Kanno Y; Saito H; Abe K; Yokokawa J; Ohira H
Intern Med; 2011; 50(12):1299-301. PubMed ID: 21673465
[TBL] [Abstract][Full Text] [Related]
17. [Treatment of primary biliary cirrhosis with ursodeoxycholic acid].
Nikolovska D; Vasilev P; Mikhova A
Vutr Boles; 2000; 32(1):25-7. PubMed ID: 11195193
[TBL] [Abstract][Full Text] [Related]
18. The long-term effect of ursodeoxycholic acid on laboratory liver parameters in biochemically non-advanced primary biliary cirrhosis.
Kuiper EM; Hansen BE; Lesterhuis W; Robijn RJ; Thijs JC; Engels LG; Koek GH; Aparicio MN; Kerbert-Dreteler MJ; van Buuren HR;
Clin Res Hepatol Gastroenterol; 2011 Jan; 35(1):29-33. PubMed ID: 20810227
[TBL] [Abstract][Full Text] [Related]
19. Biochemical responses to bezafibrate improve long-term outcome in asymptomatic patients with primary biliary cirrhosis refractory to UDCA.
Tanaka A; Hirohara J; Nakanuma Y; Tsubouchi H; Takikawa H
J Gastroenterol; 2015 Jun; 50(6):675-82. PubMed ID: 25239675
[TBL] [Abstract][Full Text] [Related]
20. Additive improvement induced by bezafibrate in patients with primary biliary cirrhosis showing refractory response to ursodeoxycholic acid.
Takeuchi Y; Ikeda F; Fujioka S; Takaki T; Osawa T; Yasunaka T; Miyake Y; Takaki A; Iwasaki Y; Kobashi H; Yamamoto K; Itoshima T
J Gastroenterol Hepatol; 2011 Sep; 26(9):1395-401. PubMed ID: 21443659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
